Ribavarin for treating Lassa fever: a systematic review of pre-clinical studies and implications for human dosing
Ribavirin is currently the standard of care for treating Lassa fever. However, the human clinical trial data supporting its use suffer from several serious flaws that render the results and conclusions unreliable. We performed a systematic review of available pre-clinical data and human pharmacokine...
Main Authors: | Salam, AP, Duvignaud, A, Jaspard, M, Malvy, D, Carroll, M, Tarning, J, Olliaro, PL, Horby, PW |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Public Library of Science
2022
|
Similar Items
-
Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): A prospective cohort study
by: Duvignaud, A, et al.
Published: (2021) -
Time to reconsider the role of ribavirin in Lassa fever
by: Salam, AP, et al.
Published: (2021) -
Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design
by: Merson, L, et al.
Published: (2021) -
Lack of evidence for ribavirin treatment of Lassa fever in systematic review of published and unpublished studies
by: Cheng, H-Y, et al.
Published: (2022) -
Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE)
by: Duvignaud, A, et al.
Published: (2020)